In vitro bactericidal activity of cefepime and cefpirome against clinical isolates at Karachi

Pakistan Journal of Pharmaceutical Sciences

Volumn 28, Issue 3, 2015, Pages 841-847

  Arsalan, Adeel ^a   Naqvi, Syed Baqar Shayam ^b   Ali, Syed Abid ^b   Ahmed, Sadia ^a   Shakeel, Osama ^c  

^a BAQAI MEDICAL UNIVERSITY   (Pakistan)

^b UNIVERSITY OF KARACHI   (Pakistan)

^c KARACHI MEDICAL AND DENTAL COLLEGE   (Pakistan)

Author keywords

Cefepime; Cefpirome; Clinical isolates; In vitro; Susceptibility

Indexed keywords

CEFEPIME; CEFPIROME; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; BURN INFECTION; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; NONHUMAN; PROTEUS; RESPIRATORY TRACT INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; URINARY TRACT INFECTION; WOUND INFECTION; BACTEREMIA; BACTERIAL SKIN DISEASE; DRUG EFFECTS; ESCHERICHIA COLI INFECTION; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PAKISTAN; PROTEUS INFECTION; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; IN VITRO TECHNIQUES; INTRAABDOMINAL INFECTIONS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PAKISTAN; PROTEUS; PROTEUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; URINARY TRACT INFECTIONS;

EID: 84929146141     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. th generation cephalosporin, resistant to beta-lactamases. Chirurgia. (Bucur), 96: 547-552.
2. Arsalan A, Sabah A, Ahmad I, Naqvi SBS, Ali SI (2010). The role of antiseptic in surgery. J. Baqai Med Univ., 13(2): 47-54.
3. Arsalan A, Anwar Z, Ahmed I, Saba A and Naqvi SBS (2013a). Microbes in pediatric infant formula. Annals. Food Sci. Technol., 14(1): 90-99.
4. Arsalan A, Anwar Z, Ahmad I, Shad Z and Ahmed S (2013b). Cronobacter sakazakii: An emerging contaminant in Pediatric infant milk formula. Int. Res. J. Pharm., 4(4):17-22.
5. Arsalan A, Naqvi SBS, Ali SI and Anwar Z (2013c). Contamination of microorganisms in pediatric infant formula. Annal. Food Sci. Technol., 14(2): 318-326.
6. Arsalan A, Naqvi SBS, Sabah A, Bano R and Ali SI (2014). Resistance pattern of clinical isolates involved in surgical site infections. Pak. J. Pharm. Sci., 27(1): 97-102.
7. Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Movahhed H, Tenney J and Martin RR (1992). Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob. Agents Chemother., 36(3): 552-557.
8. Bauer AL, Kirby WMM, Sherris JC and Turck M (1966). Antibiotic susceptibility testing by a standardized single disk method. Am. J. Clin. Pathol., 45: 493-496.
9. Bedenic B, Beader N and Zagar Z (2001). Effect of inoculum size on the anti-bacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum beta-lactamases. Clin. Microbiol. Infect., 7(11): 626-635.
10. Biek D, Critchley IA, Riccobene TA and Dirk A Thye DA (2010). Ceftaroline fosamil: A novel broad-spectrum cephalosporin with expanded anti-Grampositive activity. J. Antimicrob. Chemother., 65(4): 9-16.
11. Blumer JL, Reed MD and Knupp C (2001). Review of the pharmacokinetics of cefepime in children. Pediatr. Infect. Dis. J., 20(3): 337-342.
12. Chapman TM and Perry CM (2003). Cefepime: A review of its use in the management of hospitalized patients with pneumonia. Am. J. Respir. Med., 2: 75-107.
13. Chaudhury A. In vitro activity of cefpirome: A new fourth generation cephalosporin. Ind. J. Med. Microbiol., 21(1): 52-55.
14. Chong MN, Jin B, Chow CWK and Saint C (2010). Recent developments in photocatalytic water treatment technology: A review. Water Res., 44(10): 2997-3027.
15. Clinical and Laboratory Standards Institute (2011). Performance standards for antimicrobial disk susceptibility tests, Twenty-First International Supplement. M100-S21, CLSI, Wayne, PA, USA, pp.42-44, 68-72.
16. Craig WA (1998). Pharmacokinetic/pharmacodynamic parameters: Rationale for anti-bacterial dosing of mice and men. Clin. Infect. Dis., 26: 1-12.
17. Crokaert F (2001). Pharmacodynamics, a tool for a better use of antibiotics. Intensive Care Med., 27: 340-343.
18. da Silva Nogueira K, Daur AV, de Messias Reason IT Ana Cristina Gales AC and Costa LMD (2011). Cefepime versus extended spectrum β-lactamase-producing Enterobacteriaceae. Braz. J. Infect. Dis., 15(2): 167-169.
19. Davies J, Wendon J, Wyncoll D and Wade J (2000). Antibiotic infusions reduce the incidence of resistant organisms in liver intensive care (abstract). Intensive Care Med., 26: 269.
20. DEXA MEDICA http://www.dexa-medica.com/ourproducts/prescriptionproducts/detail.php?id=15&idc=9 (Accessed on July 03, 2013)
21. Endimiani A, Perez F and Bonomo RA (2008). Cefepime: A reappraisal in an era of increasing anti-microbial resistance. Expert Rev. Anti. Infect. Ther., 6(6): 805-824.
22. Fantin B, Farinotti R, Thabaut A and Carbon C (1994). Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. J. Antimicrob. Chemother., 33: 563-569.
23. Feglo PK, Gbedema SY, Quay SNA, Adu-Sarkodie Y and Opoku-Okrah C (2010). Occurrence, species distribution and antibiotic resistance of Proteus isolates: A case study at the komfo anokye teaching hospital (KATH) in Ghana. Int. J. Pharma Sci. Res., 1(9): 347-352.
24. Gaynes R and Edwards JR (2005). Overview of nosocomial infections caused by Gram negative bacilli. Clin. Infect. Dis., 41(6): 848-854.
25. Gupta V, Datta P, Agnihotri N and Chander J (2006). Comparative in vitro activities of seven new beta-lactams, alone and in combination with beta-lactamase inhibitors, against clinical isolates resistant to third generation cephalosporins. Braz. J. Infect. Dis., 10(1): 22-25.
26. Hafeez S, Izhar M, Ahmed A, Afia Zafar A and Naeem M (2000). In vitro Anti-microbial activity of Cefpirome: A new fourth-generation Cephalosporin against clinically significant Bacteria. J. Pak. Med. Assoc., 50(8): 250-252.
27. Harrison CJ and Denise Bratcher D (2008). Cephalosporins: A Review. Pediatric. Rev., 29(8): 264-272.
28. Isais-Agdeppa AT and Bravo L (2005). A five-year retrospective study on the common microbial isolates and sensitivity pattern on blood culture of pediatric cancer patients admitted at the philippine general hospital for febrile neutropenia. PIDSP Journal, 9(2): 19-24.
29. Jones RN and Preston DA (1983). The anti-microbial activity of cephalexin against old and new pathogens. Postgrad. Med. J., 59(5): 9-15.
30. Knox K, Lawsony W, Deanyz B and Holmesx A (2003). Multidisciplinary anti-microbial management and the role of the infectious diseases pharmacist: A UK perspective. J. Hosp. Infect., 53: 85-90
31. Lemaire S, Glupczynski Y, Duval V, Bernard Joris B, Paul M. Tulkens PM and Van Bambeke F (2009). Activities of ceftobiprole and other cephalosporins against extra cellular and intracellular (THP-1 Macrophages and Keratinocytes) Forms of methicillin-susceptible and methicillin resistant staphylococcus aureus. Anti-microb. Ag. Chemother., 53(6): 2289-2297.
32. Liao CH, Sheng WH, Wang JT Sun HY, Wang HK, Hsueh PR, Chen YC and Chang SC (2006). In vitro activities of 16 anti-microbial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan. J. Microbiol. Immunol. Infect., 39: 59-66.
33. Mouton JW and den Hollander JG (1994). Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother., 38: 931-936.
34. Nasiri MI, Naqvi SB, Zaidi AA, Saeed R and Raza G (2013). Report-comparative study on resistant pattern of clinical isolates against levofloxacin and cefepime. Pak. J. Pharm. Sci., 26(2): 415-419.
35. Noel GJ, Bush K, Bagchi P, Ianus J and Strauss RS (2008). A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis., 46: 647-655.
36. Sader HS, Gales AC, Pfaller MA, Mendes RE, Zoccoli C, Barth A and Jones RN (2001). Pathogen frequency and resistance patterns in brazilian hospitals: Summary of results from Three Years of the Sentry Anti-microbial Surveillance Program. Braz. J. Infect. Dis., 5 (4): 200-214.
37. Sadique I, Abid S, Aleem S, Anwar S, Hafeez M, Pasha MI and Butt F (2009). Single dose prophylaxis in obstetrics and gynaecological surgeries. Annals, 15(4): 176-179.
38. Sae-Tia L and Chongsomchai C (2006). Appropriateness of anti-biotic prophylaxis in gynecologic surgery at Srina-garind Hospital. J. Med. Assoc. Thai., 89: 2010-2014.
39. Sagawa T, Fuiuno T, Sakuragi N, Kishida T, Yamada H and Fuiimoto S (2000). Clinical study of cefpirome sulphate in obstetric and gynaecological infections. J. Int. Med. Res., 28(6): 288-99.
40. Santos JI, Arredondo JL and Vazquez V (2000). Bacterial isolates from hematology, oncology and intensive care units: Susceptibility to cefpirome and other beta-lactam antibiotics in a multicenter study in Mexico. Curr. Ther. Res., 61(5): 266-276.
41. Saravolatz LD, Stein GE and Johnson LB (2011). Ceftaroline: A novel cephalosporin with activity against Methicillin-resistant staphylococcus aureus. Clin. Infect. Dis., 52(9):1156-1163.
42. Ullah F, Malik SA and Ahmed J (2009). Anti-microbial susceptibility pattern and ESBL prevalence in Klebsiella pneumoniae from urinary tract infections in the North-West of Pakistan. Afr. J. Microbiol. Res., 3(11): 676-680.
43. Wiseman LR and Lamb HM (1997). Cefpirome: A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia. Drugs, 54: 117-140.
44. Witte W, Cuny C, Klare I, Nubel U, Strommenger B and Werner G (2008). Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens. Int. J. Med. Microbiol., 298(56): 365-77.
45. Wynd MA and Paladino JA (1996). Cefepime: A fourth-generation parenteral cephalosporin. Ann. Pharmacother., 30(12): 1414-1424.
46. Yoshikawa TT and Bradley SF (2002). Staphylococcus aureus Infections and Anti-biotic resistance in older Adults. Clin. Infect. Dis., 34(2): 211-216.
47. Zorgani A, Franka RA, Zaidi MM, Alshweref UM and Elgmati M (2010). Trends in nosocomial bloodstream infections in a burn intensive care unit: An eight-year survey. Ann. Burns Fire Disasters, 23(2): 88-94.